Working Together to Understand, Protect and Restore Vision
Using a stem cell-derived therapeutic developed over more than a decade in Dr. David Gamm’s lab at UW–Madison, BlueRock Therapeutics has treated the first patient in a new Phase 1/2a clinical trial aimed at a group of inherited retinal disorders (including RP and cone-rod dystrophy). The initiative is the result of a strategic research alliance formed in …
We’re pleased that Chancellor Mnookin has chosen to highlight research from MERI Director David Gamm’s lab to launch her new webpage on transformative, federally funded work happening right now at UW–Madison. You can read about the Gamm Lab’s research here and learn more about our university’s other impactful, cutting-edge research projects by visiting the Chancellor’s webpage here.
BlueRock Therapeutics LP, a clinical stage cell therapy company and subsidiary of Bayer AG, today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for OpCT-001, an investigational induced pluripotent stem cell (iPSC)-based cell therapy for the treatment of primary photoreceptor diseases. Discoveries over the past …